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Abstract
Pneumococcal meningitis is associated with substantial mortality and morbidity. We systematically assessed brain
histopathology of 31 patients who died of pneumococcal meningitis from a nationwide study (median age
67 years; 21 (67 %) were male) using a pathology score including inflammation and vascular damage. Of the 27
patients with known time from the admission to death, 14 patients died within 7 days of admission and 13 after
7 days of admission. Eleven of 25 (44 %) patients had been treated with adjunctive dexamethasone therapy.
Observed pathological processes were inflammation of medium-large arteries in 30 brains (97 %), cerebral
haemorrhage in 24 (77 %), cerebritis in 24 (77 %), thrombosis in 21 (68 %), infarction in 19 (61 %) and ventriculitis
in 19 (of 28 cases, 68 %). Inflammation of medium-large arteries led to obstruction of the vascular lumen in 14
(of 31 cases, 45 %). Vascular inflammation was associated with infarction and thrombosis of brain parenchymal
vessels. Hippocampal dentate gyrus apoptosis between patients treated with and without dexamethasone was
similar (p = 0.66); however, dexamethasone treated patients had higher total pathology score than non-dexamethasone
treated patients (p = 0.003). Our study shows that vascular damage is key in the process of brain damage in
pneumococcal meningitis. Data and material of this study will be made open-access for translational research in
pneumococcal meningitis (MeninGene-Path).
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Introduction
Bacterial meningitis is an infection of the central ner-
vous system with an incidence of 0.9–2.6 per 100.000
per year in adults in high-income countries and substan-
tially higher incidences in countries with middle- and
low-income status [1, 2]. Streptococcus pneumoniae (the
pneumococcus) is the most frequent causative micro-
organism of community-acquired bacterial meningitis,
causing 70 % of adult cases [1, 2]. Pneumococcal menin-
gitis is associated with high mortality and morbidity
rates, with 18–30 % of patients dying, and neurological
sequelae occurring in half of survivors, most commonly
hearing loss and cognitive deficits [3–6]. The poor prog-
nosis of pneumococcal meningitis has been hypothesized
to be driven by a high rate of cerebrovascular complica-
tions, mainly consisting of cerebral infarctions [7].
Few studies have systematically analysed brain autopsy
material from patients with pneumococcal meningitis
[8–10]. These studies showed that parenchymal damage
in pneumococcal meningitis is caused by the combin-
ation of cytotoxic and vasogenic oedema, compression
of vital brain structures, leukocyte infiltration, abscess
formation, and cortical necrosis [8–10]. Animal models
showed that hippocampal apoptosis was associated with
abnormal neuropsychological test results in animals after
pneumococcal meningitis, and that poor neuropsycho-
logical test results were associated with adjunctive dexa-
methasone treatment [9, 11]. Experimental animal models
of pneumococcal meningitis furthermore have shown a
large variation in histopathological features, most likely
due to different combinations of bacterial strains, infected
animal species, methods of inoculation, and stages of
infection [12–18].
Adjunctive dexamethasone is currently routine in the
treatment of adults with community-acquired pneumo-
coccal meningitis after evidence from randomized clin-
ical trial [3], meta-analyses [19–20], and nationwide
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implementation studies [21, 22]. Although dexametha-
sone has been associated with increase hippocampal
apoptosis in mice with pneumococcal meningitis [9, 11],
a long-term follow-up study of a randomized controlled
trial investigating the efficacy and safety of adjunctive
dexamethasone did not show increased neuropsycho-
logical sequelae in those treated with dexamethasone
[6].
Histopathological examination may provide insight in
pathophysiological mechanisms that take place during
pneumococcal meningitis [23]. In 2006, we started a
prospective cohort study to identify and characterize
host genetic traits and bacterial genetic factors control-
ling occurrence and outcome of bacterial meningitis
(MeninGene) [24]. Previously, we reported the inci-
dence, causative pathogens, clinical features, and prog-
nostic factors in adults with community-acquired
bacterial meningitis in the Netherlands from 2006 to
2014 [21]. Here, we report on the systematic scoring of




We identified patients with community-acquired pneumo-
coccal meningitis in whom autopsy was performed be-
tween 1985 and 2013 in the neuropathology database of
the Academic Medical Center, Amsterdam, and from two
nation-wide prospective cohort studies [3]. Methods of
both studies have been described previously [3, 22]. In
summary, all patients over 16 years of age or older who
were listed in the database of the Netherlands Reference
Laboratory for Bacterial Meningitis [22] were prospect-
ively included in these cohort studies. This laboratory
receives cerebrospinal fluid (CSF) isolates from 90 % of all
patients with bacterial meningitis in the Netherlands. The
NRLBM provided daily updates of the names of the hospi-
tals where patients with bacterial meningitis had been
admitted in the preceding 2–6 days and the names of phy-
sicians. Physicians were contacted, and informed consent
was obtained from all participating patients or their legally
authorized representatives. From the databases of these
cohorts we selected deceased patients who underwent
brain autopsy. Cases with negative CSF and blood
cultures, trauma and/or neurosurgery prior to meningitis
were excluded. If the brain autopsy was performed in a
hospital other than the AMC, histology slides, tissue
blocks and autopsy reports were requested. Informed con-
sent was obtained for brain autopsy. Tissue was obtained
and used in accordance with the Declaration of Helsinki
and the AMC Research Code.
Brains of twenty-one patients served as age, sex and
duration of hospital admission matched control samples
for the analysis on apoptosis in the hippocampal cortex.
These patients died from non-neurologic disease and
were not found to have neurological disease during life.
The causes of the death of the controls were: ten cases
of sepsis with the admission duration of 1 to 20 days,
five cases of cardiovascular accidents with the admis-
sion duration of 1 and 17 days, four cases of lung em-
bolism with duration of 1 and 6 days and one case of
respiratory failure from an acute exacerbation of end
stage chronic obstructive pulmonary disease of which
admission duration was unsure. The neuropathologist
was blinded for the patient diagnosis at the time the
brains were re-evaluated.
Histopathology
At the time of autopsy the brains were macroscopically ex-
amined by the local pathologists, followed by formalin fix-
ation and sampling of macroscopically abnormal lesions.
The sampled cut-up blocks were then embedded in paraf-
fin, cut, deparaffinized and stained for hematoxylin-eosin
(HE) at the local institutes. Other histologic and immuno-
histologic stainings such as Luxol-PAS, Nissl, Elastica van
Gieson, a number of routine neuronal and glial marker
were performed at the discretion of the pathologist. All
available slides and cut-up blocks were collected at the
AMC. All HE slides were re-evaluated by a neuro-
pathologist and scored for the following parameters: 1) se-
verity and main components of the inflammatory cells, 2)
brain parenchymal damages consisting of cerebral infarc-
tion, haemorrhage, abscess and parenchymal infiltration of
inflammatory cells, 3) inflammation in large/medium arter-
ies and small parenchymal vessels, 4) arterial, venous and
capillary thrombosis and 5) presence of ventriculitis. A Carl
Zeiss Axiopskop light microscope with 6 object lenses
of magnification of ×2, ×4, ×10, ×20, ×40 and ×100 and
LED light source was used (Wetzlar, Germany). For the
counting of apoptotic cells, the slides with hippocampus
area were scanned with A. Menarini D-Sight fluo scanner
(Florence, Italy) and the entire surface of hippocampal den-
tate gyrus were measured using the D-Sight Viewer 4.0
software (Brussels, Belgium). Apoptotic cells were identi-
fied by microscopic investigation with a 100× oil lens mag-
nification. Apoptotic cells were distinguished by the
presence of condensed chromatin with budding of nucleus
and/or apoptotic bodies (Fig. 1a). If there was doubt
whether cell types other than hippocampal cells, were
present, such as inflammatory cells, the case was excluded
for the apoptosis analysis. The number of apoptotic cells
was converted to total apoptosis/mm2.
TUNEL in situ assay
We used FD NeuroApop Kit (FD NeuroTechnologies) for
detection of DNA fragmentation in apoptosis in the hippo-
campal region. Paraffin blocks were cut in 5 μm thickness
and mounted on the slides, followed by deparaffinization
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and rehydration. After washing with PBS, the slides were
incubated with 100 μl Digestive Enzyme for 15 min. The
slides were then incubated with reaction buffer and then
with the Detection Reagent. The slides were covered with
Chromogen solution and subsequently counterstained by
incubating with Methyl Green. The process was finalized
with rehydration and cover slips mounting using per-
mount. Positive stained cells (Fig. 1b) of hippocampal den-
tate gyrus were manually counted and the number of
apoptotic cells was converted to total apoptosis/mm2.
Data analysis
Five categories were defined for histological evaluation:
meningeal infiltration of inflammatory cells, brain paren-
chymal damage, vascular inflammation, thrombosis and
ventriculitis. Brain parenchymal damage was evaluated
by assessing parenchymal infiltration of inflammatory
cells, infarction, haemorrhage and abscesses. For the
vascular inflammation, inflammation of medium-large
arteries in the meninges and small parenchymal vessels
were evaluated. Thrombosis was sub-categorized into
thrombosis of arterial, venous and small vascular throm-
bosis. Histopathological findings were scored according
to Table 1.
Continuous data are presented as medians and inter-
quartile ranges (IQR). Differences in pathology scores be-
tween patient groups were compared using a Mann
Whitney U-test for continuous variables and a Chi-square
test or Fisher’s exact test regarding dichotomous variables.
Strength of relationships between continuous variables
was assessed by Spearman’s correlation tests. All statistical
tests were 2-tailed, and a p-value of <0.05 was considered




We identified 31 cases: 12 identified from the AMC
neuropathology databank, 11 from the nationwide cohort
study 1998–2002, and 8 from the nationwide cohort study
2006–2015 [2, 6, 21]. The patient selection process is de-
scribed in Fig. 2. Out of 31 cases, a median number of 11
slides per case (IQR 7–14) were available and evaluated.
Number of brain areas evaluated per patient are noted in
Additional file 1: Table S1.
Clinical characteristics, treatment and clinical course
Baseline characteristics were available for all patients
and detailed clinical characteristics could be retrieved
from 27 patients (87 %; Table 2); 22 patients were in-
cluded in prospective clinical studies. The median age
was 67 years (IQR 46–77), and the majority was male
(64 %). Predisposing factors were present in 13 of 27 pa-
tients (48 %). All but one patient were admitted with a
decreased level of consciousness, defined a score on the
Glasgow Coma Scale (GCS) of 14 or lower, and 8 of 23
(35 %) were admitted in coma, as defined as a GCS score
below 8. The median C-reactive protein level in blood
was 303 mg/L (IQR 204–403). The median CSF
leukocyte count 657 per mm3 (IQR 51–1787). Antibiotic
treatment consisted of a third generation cephalosporin
(ceftriaxone or cefotaxime) combined with amoxicillin in
7 of 23 cases (30 %), monotherapy amoxicillin or penicil-
lin in 4 (17 %), monotherapy third generation cephalo-
sporin in 8 (35 %), and other regimens were used in 3
(13 %) patients. Adjunctive dexamethasone was given
before or with the first dose of antibiotics in 11 of 25
cases (44 %) including 10 patients (40 %) who received
dexamethasone 10 mg QID for 4 days according to
Fig. 1 Apoptotic cells in hippocampus dentate gyrus. a Overview of hippocampus in HE stain. The apoptotic cells are marked with red dots. b–d
Three apoptotic cells are indicated by arrows and magnified in b, c and d. Arrows again indicate the apoptotic cells. e. TUNEL analysis. Arrows
indicate the positive cells
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current guidelines [22]; 5 additional patients received
dexamethasone after the first dose of antibiotics or after
clinical deterioration. Baseline characteristics, clinical
presentation and complications were similar between
patients receiving adjunctive dexamethasone with or
before the first dose of antibiotics and those who did
not (Additional file 2: Table S2).
Neurological complications developed during clinical
course in 22 of 23 patients (96 %), and systemic complica-
tions in 21 of 23 patients evaluated (91 %). A clinical diag-
nosis of stroke was made in 13 of 20 (65 %), and consisted
of cerebral infarction in 11 (55 %) and cerebral haemor-
rhage in 2 (10 %). Three patients were clinically diagnosed
with secondary deterioration due to multiple cerebral in-
farctions, consistent with the diagnosis of delayed cerebral
thrombosis [25, 26]. The time from admission to death
was known for 27 of 31 patients (87 %). Fourteen patients
died within 7 days of admission and were considered to be
in the early phase of meningitis (median duration of dis-
ease 3 days, IQR 2–4). Thirteen cases with a time to death
of 7 days or longer were classified as late phase, with a
median duration of disease of 27 days (IQR 16–31).
Total pathology score
The median total pathology score was 15 (IQR 10–20;
maximal score is 33; Table 3). Total pathology score was
associated with age (older than 60 years, 11 [IQR 9–20]
vs. 60 years or younger, 18 [IQR 12–21]; p = 0.042).
None of the other clinical features or laboratory results
was associated with pathology scores. However, patients
treated with dexamethasone started prior to or together
with the first dose of antibiotics had a higher median
total pathology score (median total pathology score 18
[IQR 17–24] vs. 11 [IQR 7–17]; p = 0.003). Patients
treated with dexamethasone had higher scores on paren-
chymal infiltration, infarction and bleeding (Additional
file 2: Table S2), but not for thrombosis of arteries, veins
and capillaries (data not shown). Causes of death were
determined in 16 of 31 patients and listed in Additional
file 3: Table S3.
Patients treated with dexamethasone prior to or to-
gether with the first dose of antibiotics died more often
because of cerebral causes than systemic causes (9 of 9
[100 %] vs. 2 of 6 [33 %]; p = 0.01).
Meningeal inflammation
Meningeal inflammation was present in all 31 evaluated
patients. Three cases (10 %) showed focal mild inflam-
mation in the subarachnoid space (Fig. 3a), 10 (32 %)
multifocal mild/focal severe/moderate (Fig. 3b) and 18
(58 %) multifocal severe meningeal inflammation
(Fig. 3c). A dominant polymorphonuclear leucocytosis
Table 1 Histopathological scoring of pneumococcal meningitis
Scoring criteria Scores
Main category Subcategory 0 1 2 3
Meningeal
infiltration




























infiltration/reactive changes or focal
severe (sub)-endothelial infiltration
with obstruction of vascular lumen




with obstruction of vascular
lumen and/or extension of






Absent Focal mild with partial
obstruction of vascular
lumen
Multifocal mild with partial
obstruction of vascular lumen or
focal severe with complete
obstruction of vascular lumen and
destruction of vessel wall
Multifocal severe with
complete obstruction of





Ventriculitis Absent A few inflammatory cells
in the ventricle
Groups of inflammatory cells in the
ventricle with/without ependymal
infiltration
Extension of inflammatory cells
into the periventricular tissue
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(Fig. 3d), defined as more than 90 % polymorphonuclear
leukocytes in the subarachnoid space, was seen in 11 of 14
early phase patients (79 %). Over time, increasing with the
days between admission and death, the proportion of
polymorphonuclear leukoyctes decreased; late cases
showed monocyte dominancy with an estimated macro-
phage ratio of 80–90 % (in 10 of 13 patients [77 %],
Fig. 3e). However, three late phase patients showed a per-
sistent polymorphonuclear leukocytosis of more than
50 % despite a duration between admission and death of
10, 30 and 31 days (Fig. 3f).
Brain parenchymal damage
Parenchymal infiltration of inflammatory cells (cerebritis,
Fig. 3w) was seen in 24 of 31 cases (77 %); six cases (19 %)
with focal mild infiltration, 12 (38 %) with multifocal mild
or focal severe and 6 (19 %) with extensive infiltration,
distributed over similar proportions for early and late
phase patients (10 of 14 [71 %] vs. 10 of 13 [77 %]; p =
0.74). Direct infiltration of inflammatory cells in the brain
parenchyma usually was limited to the superficial part of
cortex. Extensive parenchymal infiltration of inflammatory
cells occurred primarily at the site of parenchymal tissue
damage, for instance in areas of infarction, haemorrhage
or abscess formation.
Cerebral infarction was identified in 19 patients (61 %);
2 cases (6 %) with focal small infarction (Fig. 3g), 4 (13 %)
with multifocal small/focal large infarction (Fig. 3h) and
13 (42 %) with extensive infarction (Fig. 3i). Cerebral
haemorrhage was seen in 24 patients (77 %); 13 (42 %)
with focal small haemorrhage (Fig. 3j), 3 (10 %) with
multifocal small/focal large haemorrhages (Fig. 3k) and 8
(26 %) cases with multifocal large haemorrhages (Fig. 3l).
17 patients (55 %) had both cerebral infarction and haem-
orrhage. Only 5 patients (16 %) had neither infarction nor
bleeding. Infarction was more frequently observed in the
late phase than in the early phases (11 of 13 patients
[85 %] vs. 5 of 14 patients [36 %], p = 0.001), while pres-
ence of haemorrhage was not related to disease duration
(11 of 13 patients in the late phase [85 %] vs. 9 of 14 pa-
tients in the early phase [64 %], p = 0.23). Patients without
infarction or haemorrhage all died early (<5 days). Cranial
CT or MRI was performed in 20 of 27 (74 %) patients
upon admission and in 16 patients (59 %) during admis-
sion, and showed cerebral haemorrhage in two patients
and cerebral infarction in nine patients. Cerebrovascular
complications on cranial imaging were not significantly
associated with cerebral infarctions or haemorrhages
observed in the pathological analysis. Whether cranial
imaging was performed and timing between admission,
cranial imaging and death varied considerably between
patients which may have contributed to the lack of
radiological-pathological correlation.
Brain abscess (Fig. 3x) was present in 6 of 31 cases
(19 %), and all were focal and small: 4 patients in early
phase and 2 in late phase cases. Identified abscesses were








13 brain autopsies (12%)





25 brain autopsies (14%)
8 available for re-evaluation
Slides available for re-evaluation:
- Cerebral cortex 31 cases
- Basal ganglia 23 cases
- Hippocampus 22 cases
- Cerebellum 22 cases
Fig. 2 Flow chart patient selection
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Table 3 Summary of pathological findingsa
All patients Score Early phaseb Score Late phaseb Score
Meningeal inflammation 31/31 (100 %) 3 14/14 (100 %) 3 13/13(100 %) 2
Infarction 19/31 (61 %) 2 5/14 (36 %) 0 11/13 (85 %) 3
Haemorrhage 24/31 (77 %) 1 9/14 (64 %) 1 11/13 (85 %) 1
Abscess 6/31 (19 %) 0 4/14 (29 %) 0 2/13 (15 %) 0
Parenchymal infiltration of inflammatory cells 24/31 (77 %) 2 10/14 (71 %) 1 10/13 (77 %) 2
Inflammation of medium large arteries in meninges 30/31 (97 %) 2 14/14 (100 %) 2 12/13 (92 %) 2
Inflammation of small parenchymal vessels 29/31 (94 %) 3 14/14 (100 %) 3 11/13 (85 %) 2
Thrombosis of medium-large arteries in meninges 15/31 (48 %) 0 4/14 (29 %) 0 9/13 (69 %) 2
Thrombosis of veins in meninges 5/31 (16 %) 0 3/14 (21 %) 0 2/13 (15 %) 0
Thrombosis of small parenchymal vessels 14/31 (45 %) 1 2/14 (15 %) 0 9/13 (69 %) 2
Ventriculitis 19/28 (68 %) 1 10/12 (83 %) 2 7/12 (58 %) 1
Total Pathology Score 31/31 (100 %) 15 14 (100 %) 14 13 (100 %) 17
aData are n/N (%), or median pathology score. bEarly phase was defined as death <7 days, late phase >7 days
Table 2 Patient characteristicsa
Characteristic n/N (%) Characteristic n/N (%)
Age (years) 67 (46–77) Indexes of inflammation in CSFe
Female 11/31 (36 %) Leukocyte count (cells/mm3) 656 (51–1787)
Predisposing factors 13/27 (48 %) Protein level (g/L) 5.1 (2.4–7.2)
Otitis/sinusitis 7/25 (28 %) CSF/blood glucose ratio 0.01 (0.00–0.15)
Pneumonia 6/24 (25 %) Antibiotic treatment
Immunocompromised stateb 7/27 (26 %) 3rd gen cephalosporin + amoxicillin 7/23 (35 %)
Symptoms and signs on admission 3rd gen cephalosporin 8/23 (30 %)
Duration of symptoms >24 h 12/23 (53 %) Amoxicillin or penicillin 4/23 (17 %)
Headache 9/17 (53 %) Other regimens 3/23 (13 %)
Nausea 8/15 (53 %) Adjunctive dexamethasone
Temperature ≥38 °C 14/21 (67 %) Started before or with first dose antibiotics 11/25 (44 %)
Neck stiffness 8/22 (36 %) 10 mg QID 4 days 10/25 (40 %)
Triad of neck stiffness, fever and altered mental status 8/22 (36 %) Started after first dose of antibiotics 5/25 (20 %)
Seizures 8/23 (35 %) Complications
Score on Glasgow Coma Scalec 10 (7–11) Cardiorespiratory failure 17/26 (74 %)
Altered mental state (GCS <14) 22/23 (96 %) Mechanical ventilation 18/22 (82 %)
Coma (GCS <8) 8/22 (36 %) Seizures 8/19 (30 %)
Focal neurological deficits Cerebral infarction 8/18 (44 %)
Blood chemistry testsd Cerebral haemorrhage 2/18 (11 %)
Leukocyte count (x109/L) 15 (8–20) Cerebral herniation 3
Thrombocyte count (x109/L) 189 (133–274) Time to death (days)f 7 (3–30)
C-reactive protein (mg/L) 303 (204–403) Early death (<7 days) 14/27
Erythrocyte sedimentation rate (mm/h, range) 51 (40–90) Range 2–62 days
aData are presented as n/N (%) or median (interquartile range) bDefined as the use of immunosuppressive drugs, a history of cancer or diabetes mellitus.
cGlasgow Coma Scale score was known for 23 patients. dLeukocyte count was known for 25 patients, thrombocyte count in 24 patients, serum C-reactive protein
(CRP) levels in 15 patients, Erythrocyte sedimentation rate (ESR) in 15 patients. eCSF leukocyte count was known in 23 patients, CSF protein concentration in 20
patients, CSF to blood glucose ratio in 23 patients. fTime from admission to death was known for 27 patients











Fig. 3 (See legend on next page.)
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small with a median diameter of 3 mm (range 1-6 mm).
Clinical data were available for 5 of patients with abscess
formation; one died on hospital arrival prior to treat-
ment or investigations. None of the other 4 patients
were diagnosed with brain abscess prior to autopsy.
Vascular inflammation
Various degrees of inflammation of large-medium arteries
and the consequent reactive changes were seen in 30 of
31 patients (97 %). The early phase patients showed sub-
endothelial influx of neutrophils in the arteries with endo-
thelial damage. The subendothelial accumulation of neu-
trophils (subendothelial pus) can be mild with open
lumen (Fig. 3m). In 6 of 14 early phase cases (43 %), how-
ever, a severe narrowing of the vascular lumen was seen
by the subendothelial pus (Fig. 3n), of which 5 cases had
complete obstruction of arteries. The vascular inflamma-
tion extended into the tunica media with destruction of
tunica elastica layer (Fig. 3o) in 3 of 14 early phase pa-
tients (21 %). Vascular inflammation in late phase cases
was characterized by reactive changes, represented as
broadened tunica intima with formation of connective tis-
sue infiltrated by various quantities of mixed inflammatory
cell composed of macrophages, lymphocytes, plasma cells
and neutrophils, as a result narrowed vascular lumen
(Fig. 3p). These reactive changes in vascular inflammation
led to severe narrowing of the arterial lumen in 8 of 13
cases (62 %). Presence of complete obstruction of arteries
was seen in 7 of 13 cases ([54 %], Fig. 3q). In one late
phase case, dilatation of arteries was seen as a result of de-
struction of tunica media (Fig. 3r). Inflammation of small
vessels was observed in 29 of 31 cases (94 %, Fig. 3s); five
patients (16 %) with focal mild, 8 (26 %) with multifocal
mild or focal severe and 16 (52 %) with multifocal severe
small vascular inflammation. In 9 of 13 late cases (69 %),
the inflamed small vessels were destructed and occluded
with connective tissue reaction (endarteritis obliterans,
Fig. 3t).
Presence of vascular inflammation was associated with
the clinical diagnosis of infarction: clinical diagnosed cere-
bral infarction was observed in 2 of 12 (17 %) cases with-
out vascular inflammation compared to 12 of 19 (63 %)
cases with vascular inflammation (p = 0.01). Arterial
thrombosis was associated with co-existing capillary
thrombosis (capillary thrombosis present in 13 of 16 with
arterial thrombosis vs. 2 of 15 without arterial thrombosis;
p = 0.002).
Thrombosis and ventriculitis
Thrombosis, thrombo-embolism and/or sinus thrombosis
was observed in 21 of 31 patients (68 %). Thrombosis of
arteries (Fig. 3v) was more frequently observed in the late
phase than the early phase (9 of 13 late phase cases [69 %]
vs. 4 of 14 early phase cases [29 %]; p = 0.04). Thrombosis
of parenchymal small vessels (Fig. 3t) was also more fre-
quently seen in the late phase (9 of 13 late phase cases
[69 %] vs. 2 of 14 early phase cases [15 %], p = 0.004).
Venous thrombosis was found in 3 of 14 patients in the
early phase (21 %) vs. 2 of 13 patients in the late phase
(15 %; p = 0.69). The ventricle was sampled in 28 cases; 12
early phase cases, 12 late phase cases and 4 with unknown
duration of disease. Ventriculitis was present in 19 pa-
tients (68 %), 10 of 12 patients in the early phase (83 %)
and 7 of 12 patients in the late phases (58 %), p = 0.18.
Seven cases showed focal mild ventriculitis (2 of 12 early
phase cases [17 %] vs. 5 of 12 late phase cases [42 %], p
= 0.18) and 9 cases were with more extensive inflamma-
tion, but still limited in the ependyma. More severe
inflammation with periventricular involvement of the
inflammation was seen in two patients, both in the
early phase.
Apoptosis of hippocampal dentate gyrus
Of the 31 meningitis cases, HE staining of hippocampus
was available for 21 patients (median age 68 years [IQR
46–76]; male-female ratio of 13:8). The time between
admission and death was known in 17 cases (median,
(See figure on previous page.)
Fig. 3 Pathological findings in pneumococcal meningitis. Short illustration of histological abnormalities. The score is based on severity of each
lesion and also extensiveness/multifocality of the histological abnomalities. a–c Meningeal inflammation: Little (a), moderate (b) and extensive (c)
infiltration of neutrophils in the sub-arachnoid space. d–f Meningeal inflammation components: mainly neutrophils (d), mainly macrophages (e)
and mix of neutrophils and macrophages (f) in a late phase case. g–i Infarction: focal small hypoxic-ischemic neuronal injury with eosinophilic
neurons (g), focal large established infarct with tissue degeneration and infiltration of inflammatory cells (h) and one of multifocal large infarcts
with gliosis in the late phase (i). j–l Haemorrhage: focal small perivascular haemorrhages (j), multifocal parenchymal moderate size haemorrhages
(k) and multifocal large haemorrhage (l). m–o Large-medium size meningeal arterial inflammation in the early phase: mild (m, admission day 3)
and severe sub-endothelial inflammation with near obstruction of vascular lumen in n (admission day 3). In o (admission day 3), vascular inflammation
extends into the tunica media with destruction of elastica layer. p–r Pathological changes of large-medium size arteries in the late phase: broadened
tunica intima with formation of connective tissue infiltrated by various quantities of mixed inflammatory cell composed of macrophages, lymphocytes,
plasma cells and neutrophils (p, admission day 18), reactive change of artery with thickening of tunica intima with near obstruction of lumen
(q, admission day 21), and reactive change of artery with tunica media degeneration and dilation (r, admission day 30). s–u Pathological
changes of small brain parenchymal vessels: inflammation (s), total destruction and degeneration (t) and thrombosis (u). v–x Thrombosis and
parenchymal infiltration of inflammatory cells: thrombosis of artery with total obstruction (v), parenchymal infiltration of inflammatory cells (w, neutrophils
are marked with asterick) and a small abscess in basal ganglia (x)
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8 days [IQR 2–20]). There were 21 control non-
meningitis cases (median age 70 year [IQR 53–77];
male-female ratio of 13:8). For controls the median days
between hospital admission and death was 7 days (IQR
2–14). The median hippocampal dentate gyrus surface
evaluated was 0.81 mm2 for cases (IQR 0.66–0.93 mm2)
and median 0.65 mm2 (IQR 0.54–0.73 mm2) for con-
trols. Morphologic evaluation of apoptotic cells in HE
staining showed a median of 3 apoptotic cells (IQR 1–9)
per mm2 in cases and 0 apoptotic cells (IQR 0–7) per
mm2 in controls.
For TUNEL assay paraffin blocks of hippocampus
were available for 13 patients with pneumococcal men-
ingitis and 20 controls; these samples were used for
morphologic analysis in HE staining. The median total
surface of the hippocampal dentate gyrus was 0.76 mm2
(IQR 0.66–0.90 mm2) for meningitis patients and
0.66 mm2 (IQR 0.56–0.73 mm2) for controls. There was
no significant difference seen in the number of apoptotic
cells between the case and control groups, neither in
morphologic analysis in HE staining (median 3/mm2 in
patients vs. 0/mm2, in controls p = 0.12) or in TUNEL
assay (median 2/mm2 in patients vs. 7/mm2, in controls
p = 0.19).
Information on adjunctive dexamethasone therapy was
available for 16 of 21 patients with morphologic analysis
of HE staining: 11 received dexamethasone and 5 did
not. The median number of apoptotic cells was similar
between groups (5/mm2vs. 3/mm2; p = 0.66). There were
no associations between the total number of apoptotic
cells and the total surface of dentate gyrus, age, the
interval from onset of symptoms to death and the path-
ology scores (data not shown).
Discussion
Our study shows that vascular damage is key in the
process of brain damage in pneumococcal meningitis.
All patients had medium-large artery inflammation,
cerebral haemorrhage, and infarction. Gross changes,
such as pressure coming, which have been described as
an obvious cause of death in pneumococcal meningitis,
were rarely found. Previous autopsy studies showed in-
flammatory infiltration of cerebral veins and arteries
[27–29], but did not correlate these findings with clinical
data. In the current study we showed that in early dis-
ease phase, severe narrowing of the vascular lumen was
mainly caused by subendothelial pus with subsequent
haemorrhages. In the late phase of disease, after seven
days of admission, the narrowed vascular lumen was
characterized by reactive vascular changes, represented
as broadened tunica intima with formation of connective
tissue infiltrated by various quantities of mixed inflam-
matory cells.
We did not observe extensive parenchymal leukocyte
infiltration. Extensive infiltration of inflammatory cells
occurred primarily at the site of parenchymal tissue
damage, for instance in areas of infarction, haemorrhage
or abscess formation. This finding is consistent with
previous experimental studies, showing that leukocyte
infiltration into the brain parenchyma has only been
observed during late infection and in the direct vicinity
of the fluid-filled spaces [17, 30]. Other elements pre-
viously described leading to permanent brain injury
such as cortical necrosis, cerebral oedema, hydroceph-
alus, hippocampal apoptosis do occur but seem to be
less essential as previously thought [9, 11, 23, 31]. Our
data suggest that future studies should focus on gener-
alized dampening of the inflammatory response in the
very early phase of disease [23], for example using ad-
junctive dexamethasone therapy, complement inhib-
ition [23, 32, 33], or target the pathological changes in
the brain vasculature.
Vascular inflammation can be divided in early and
late phase characteristics. We observed inflammation of
medium large arteries in meninges in the early phase
with endothelial swelling and/or ulceration, inflammation
and necrosis of tunica media and thrombus forming. This
finding is consistent with previous reports [8, 28]. System-
atic analysis of the frequency and severity of the vascular
inflammation showed that all patients exhibit arterial
inflammation, with mild narrowing of lumen to (near)
obstruction, resulting in vascular obstruction in the major-
ity of patients. This severe narrowing and obstruction of
the arterial lumen is an important mechanism of brain
parenchymal infarction in pneumococcal meningitis, espe-
cially in the early phase where thrombosis plays a less
important role. This is in line with a retrospective trans-
cranial doppler study of in 94 patients with acute bacterial
meningitis, showing increased cerebral blood flow velocity
in about half of patients, which was associated with in-
creased risk of cerebral infarction (odds ratio 9.15; 95 %
confidence interval 1.96–42.67) [34]. The ongoing reactive
changes of medium large arteries, which again causes
narrowing and obstruction of the vascular lumen, as well
as thrombus formation in the arteries and small vessels,
are likely to be responsible for the increased frequency
and severity of infarctions in the late phase.
The pathogenesis of cerebral infarction is a subject of
ongoing research, which has focused largely on two areas:
first, the dysregulation of the coagulation and fibrinolysis
[35, 36], not only systemically but also locally [37, 38], as
exemplified by the upregulation of plasminogen activator
inhibitor-1 and elevated levels of prothrombin fragments
F1 and −2 and soluble tissue factor in the CSF of patients
with pneumococcal meningitis [36]; and second, endothe-
lial cell dysfunction, which may lead to localized swelling
and release of pro-coagulant factors and proinflammatory
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cytokines [39–41]. Our data suggest an important role for
cerebral (micro)haemorrhages. Although speculative, we
hypothesize that in early phases, bacteria indeed adhere to
blood vessel endothelium of the blood-brain-barrier using
complex mechanisms such as binding of endothelial lam-
inin receptor, PAF receptors and intercellular transloca-
tion [23]. Subsequently, bacteria may well bluntly disrupt
and invade the basement membrane, causing (micro)he-
morrhages, which may well result in secondary cerebral
infarction through vessel thrombosis, vasospams, and loss
of cerebral autoregulation. Alternatively, massive clotting
may also result in local depletion of clotting factors,
thereby introducing micro-hemorrhages [23]. Few studies
addressed visualization of bacterial growth and spread to
the central nervous system from blood by breaching the
multiple layers of meninges and brain-blood barrier. Many
questions remains unanswered, such as how the bacteria
invade the brain parenchyma and how bacteria cause the
large and small vascular inflammation.
We found that adjunctive dexamethasone treatment
started prior to or with the first dose of antibiotics was
not associated with increased hippocampal apoptosis.
Cognitive impairment is a frequent complication in adults
who survive bacterial meningitis [42]. Because corticoste-
roids may potentiate ischemic injury to neurons [43], it is
important to know whether dexamethasone prevents
death but worsens cerebral functioning. An experimental
pneumococcal meningitis study identified aggravated
apoptosis in the hippocampus of infant rats treated with
dexamethasone, which was associated with learning defi-
ciency [11]. We did not detect any differences in the num-
ber of apoptotic cell in the hippocampal dentate gyrus
using HE and TUNEL between patients treated with or
without dexamethasone. Furthermore, we did not find any
differences in dentate gyrus apoptosis between meningitis
patients and controls. This is in contrast with a previous
study showing that described hippocampal apoptosis
demonstrated by HE and TUNEL assay in 26 brains from
bacterial meningitis patients of whom nine had
pneumococcal meningitis [9]. Results of our and this
study are, however, difficult to compared due to differ-
ences in analyses and included populations. Our results
imply the role of hippocampal apoptosis is limited in
pneumococcal meningitis, and are in line with a follow-
up study of the European Dexamethasone Study that
described that treatment with adjunctive dexametha-
sone is not associated with an increased risk for long-
term cognitive impairment [6].
Adjunctive dexamethasone treatment was associated
with more brain pathology. Brains of the patients
treated with dexamethasone showed more infarctions,
haemorrhages, arterial inflammation and parenchymal
infiltration of inflammatory cells. Patients treated with
dexamethasone all died due to neurological causes
whereas the majority of non-dexamethasone treated pa-
tients died due to systemic causes. This is in line with
the finding that the beneficial effect of dexamethasone
on mortality rates in patients with pneumococcal men-
ingitis is attributable to a beneficial effect on systemic
complications [44].
Our study has several limitations. First, autopsy is
only performed in approximately 20 % of deceased pa-
tients in our cohort studies and brain autopsy was not
performed in all of them. For both cohorts together we
were able to re-evaluate brains of 5 % of deceased pa-
tients [2, 22]. Although this is only a small proportion
of potential cases, it is unlikely the sample has a selec-
tion bias that would decrease the value of the analysis.
Second, we were also limited to microscopic investiga-
tion of different quantity of slides from varying brain
regions. Conclusions of pathology analysis and clinical-
pathological correlations were based on a limited num-
ber of observations (slides) per brain and therefore
may suffer from sampling error. Third, several patients
were identified retrospectively from the AMC neuro-
pathology database, and clinical data could not or only
partially be retrieved for some of them. This resulted
in missing data on duration of disease in four patients
that may therefore potentially have died from different
causes than meningitis. However, in these patients the
autopsy reports did not indicate a different cause of
death. Fourth, we did not have data on onset of ther-
apy or exact duration of disease before admission,
which, if unevenly distributed between dexamethasone
groups, may be a confounding factor. Finally, to what
extent the described pathology processes occur in pa-
tients surviving pneumococcal meningitis cannot be
determined from our study. Nevertheless, our series is
currently the largest collection of pathological analysis
with clinical data, and provides valuable leads for fur-
ther pathophysiological studies. This work is part of a
prospective cohort study to identify and characterise
host genetic traits and bacterial genetic factors con-
trolling occurrence and outcome of bacterial meningi-
tis (MeninGene) [21, 24]. We are currently working on
digitalization of our pathology material, which will be
made publically accessible (MeninGene-Path). Speci-
mens will also be made available for further imaging
and expression studies.
Conclusion
Vascular inflammation plays an important role in brain
damage of pneumococcal meningitis throughout the
whole disease process, from the early to late phases.
Dexamethasone was not shown to have significant influ-
ence in hippocampal apoptosis, Brains of the patients
treated with dexamethasone showed however more
Engelen-Lee et al. Acta Neuropathologica Communications  (2016) 4:26 Page 10 of 12
pathological changes, which is probably attributable to
the beneficial effect of dexamethasone on mortality rates
in patients with pneumococcal meningitis as a result of
its beneficial effect on systemic complications.
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